Latest Partnerships News

Critical Resources Limited showcased its diversified critical metals portfolio and advanced battery tech at its 2026 AGM, spotlighting growth prospects in lithium, gold, and base metals across Australia, Canada, and New Zealand.

Cooks Coffee Company reported a 22.8% jump in group store sales and a 27% rise in normalised EBITDA for FY26, driven by strong UK and Ireland growth and new international franchise agreements.

Global Lithium Resources has completed a strategic placement raising A$7.32 million from Lopal, cementing a key partnership and advancing its Manna Lithium Project toward a final investment decision.

Ventia Services Group has landed a NZD 125 million contract to maintain and renew roads for New Zealand's Far North District Council, marking a significant expansion of its infrastructure services footprint.

Volt Group reported an 8% revenue decline in FY25 amid strategic shifts but is poised for growth with the 4D Delta acquisition driving a 150% revenue surge in Q1 FY26.

Champion Iron Limited reported a 19% increase in net profit to C$168.7 million for FY2026, driven by record production and sales, progress on its DRPF project, and the strategic acquisition of Rana Gruber.

Pure Resources (ASX: PR1) has closed a $3 million placement, issuing 12 million shares after shareholder approval, while also issuing options and advisory shares to support exploration and cutting-edge carbon nanotube fibre research.

Actinogen Medical has obtained positive scientific advice from the European Medicines Agency that aligns with prior FDA guidance, clarifying regulatory requirements for its Alzheimer’s drug Xanamem and paving the way for a streamlined approval process in major markets.

Nexalis Therapeutics has locked in a $53 million non-dilutive funding facility with Point8 Capital, replacing its previous lender and supporting three clinical programs targeting breakthrough cancer pain, panic disorder, and treatment-resistant depression.

BPH Global Ltd (ASX: BP8) posted its second best monthly seaweed trading result with gross sales of approximately A$391,000 in the twelfth month, pushing aggregate sales beyond A$3.3 million as Indonesian operations scale up post-monsoon.

The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.

Imugene has dosed the first patient in a new cohort combining its azer-cel CAR T therapy with BTK inhibitors, targeting patients with B-cell malignancies who failed prior BTKi treatment. This move broadens the trial’s scope and tackles a significant unmet need in blood cancer therapy.